Literature DB >> 22970045

Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma.

Jian Xu1, Hong Zhu, Yaqin Zhao, Xin Wang, Yali Shen, Wu Wang, Feng Xu.   

Abstract

In the present study, we reviewed 44 postgastrectomy adenocarcinoma patients who had hepatitis B and received treatment in the Abdominal Cancer Department of the West China Hospital between October 2006 and October 2010. Of these patients, 17 developed hepatic dysfunction. Radiotherapy is an independent risk factor to hepatic function on univariate and multivariate analysis. Grade III or IV hepatic dysfunction was developed by five patients, all of whom had received radiotherapy and had reactivated hepatic B virus (HBV). Radiotherapy is a significant risk factor to hepatic function in patients with postgastrectomy adenocarcinoma carrying HBV, thus we suggest excluding the liver from the radiation field. HBV reactivation plays a role in the development of grade III or IV hepatic dysfunction. Patients with reactivated HBV should immediately receive regular antiviral treatment.

Entities:  

Year:  2012        PMID: 22970045      PMCID: PMC3439092          DOI: 10.3892/ol.2012.745

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.

Authors:  Beibei Zhang; Junxue Wang; Wensheng Xu; Lei Wang; Wu Ni
Journal:  Onkologie       Date:  2010-09-10

2.  Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.

Authors:  Fiona L Day; Emma Link; Karin Thursky; Danny Rischin
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

3.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

4.  Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.

Authors:  Kosei Matsue; Shun-ichi Kimura; Yoko Takanashi; Kan-ichi Iwama; Hideaki Fujiwara; Masayuki Yamakura; Masami Takeuchi
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

5.  Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.

Authors:  Nozomi Niitsu; Yuki Hagiwara; Ken Tanae; Mika Kohri; Naoki Takahashi
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

6.  Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.

Authors:  A Yuriko Minn; Annie Hsu; Trang La; Pamela Kunz; George A Fisher; James M Ford; Jeffrey A Norton; Brendan Visser; Karyn A Goodman; Albert C Koong; Daniel T Chang
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

7.  Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.

Authors:  Sylvia Brost; Paul Schnitzler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

8.  Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.

Authors:  Dongmei Ji; Junning Cao; Xiaonan Hong; Junmin Li; Jianmin Wang; Fangyuan Chen; Chun Wang; Shanhua Zou
Journal:  Eur J Haematol       Date:  2010-05-20       Impact factor: 2.997

9.  Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.

Authors:  Yu Xuan Koo; Daniel S W Tan; Iain B Tan; Miriam Tao; Wan Cheng Chow; Soon Thye Lim
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

10.  American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

Authors:  Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

View more
  3 in total

Review 1.  Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.

Authors:  Sonali Paul; Akriti Saxena; Norma Terrin; Kathleen Viveiros; Ethan M Balk; John B Wong
Journal:  Ann Intern Med       Date:  2015-11-24       Impact factor: 25.391

2.  Gemcitabine plus S-1 for metastatic pancreatic cancer.

Authors:  Hong Zhu; Cheng Yi; Yaqin Zhao; Hongfeng Gou
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

3.  Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer.

Authors:  Zhiping Li; Jianshuang Zeng; Zi Wang; Hong Zhu; Yuquan Wei
Journal:  Oncol Lett       Date:  2014-07-18       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.